Yu Tian

Yu Tian

Auto-generated profile, based on publicly available information

Yu Tian

School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Science Advances
Verified
Journal Article
Open access
ZMZhen Ma
Zhen Ma
YLYunpeng Ling
Yunpeng Ling
RGRui Guo
Rui Guo
YTYu Tian
Yu Tian
YZYongbin Zheng
Yongbin Zheng
YLYunpeng Ling
Yunpeng Ling
Following myocardial infarction (MI), the accumulation of CD86-positive macrophages in the ischemic injury zone leads to secondary myocardial damage. Precise pharmacological intervention targeting this process remains challenging. This study engineered a nanotherapeutic delivery system with CD86-positive macrophage-specific targeting and ultrasound-responsive release capabilities. A folic acid (FA)–modified ultrasound-responsive gene/drug delivery system, assembled from DOTAP, DSPE-PEG2000-FA, cholesterol, and perfluorohexane (PFH)—termed FA-PNBs—was developed to codeliver small interfering RNA of STAT1 (siSTAT1) and the small-molecule nitro-oleic acid (OA-NO 2 ) into CD86-positive macrophages. Upon irradiation with low-intensity focused ultrasound, FA-PNBs release siSTAT1 and OA-NO 2 at the ischemic injury zone. The results demonstrated the system’s precise targeting and efficient delivery capabilities. The combined modulation of OA-NO 2 and siSTAT1 optimizes the immune microenvironment in the infarcted region, alleviates ventricular remodeling, preserves cardiac function, and holds promise for clinical intervention strategies after MI.

11 June 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
YTYu Tian
Yu Tian
YLYutong Liu
Yutong Liu
YTYuhao Tong
Yuhao Tong
KHKristin Huntoon
Kristin Huntoon
LYLiqun Yang
Liqun Yang
ALAndrew S. Lee
Andrew S. Lee